Enteral Nutrition Tolerance and the Gut Microbiome Study

Sponsor
Mayo Clinic (Other)
Overall Status
Recruiting
CT.gov ID
NCT03795870
Collaborator
(none)
50
1
2
48.7
1

Study Details

Study Description

Brief Summary

The current study will enroll patients who are going to require enteral nutrition support for at least 4 weeks and randomize them to standard polymeric formulas or blenderized tube feeding. They will be asked to fill out a questionnaire about their tolerance of enteral feeds. They will also be asked to provide stool samples before enrollment and after 4-6 weeks.

The study is trying to assess whether the use of whole food in blenderized tube feeding will be better tolerated and also lead to greater diversity of microbiome.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Polymeric Tube Feeds
  • Dietary Supplement: Blenderized Tube Feeds
N/A

Detailed Description

Malnutrition remains highly prevalent in both acute and chronic diseases, leading to longer hospital length of stay, greater risk of hospital readmission, and overall increase in morbidity and mortality. Over the last few decades, studies have continued to reveal significant clinical benefit from nutrition support, including reduction in complications and length of stay, maintenance of gastrointestinal integrity, and overall improvement in clinical outcomes and mortality. Despite high prevalence of Home Enteral Nutrition(HEN), patients continue to struggle with intolerance of tube feeds leading to chronic underfeeding and weight loss. Current guidelines recommend using standard polymeric formula or high-protein standard formula in the hospitalized patient requiring EN and also recommend against routine use of formulas designed to be immune-modulatory, elemental/semi-elemental, disease-specific (diabetes), and organ-specific (hepatic, renal, pulmonary).

Blenderized Tube Feeding(BTF) offers a number of advantages to standard polymeric formula including being able to modify the macro-nutrient and fiber content based on patient preference. BTF use has also been increasing significantly in the past few years.

The gut microbiome, or gut host environment, consists of approximately 10 thousand cells and has been the subject of much interest as it relates to gastrointestinal homeostasis. Our aim therefore is to (1) characterize the structure and dynamics of complex microbial communities using 16S rRNA- encoding gene sequences; (2) determine how they change with EN and; (3) how they may be correlated with tolerance of EN.

A total of fifty subjects who are willing to participate in current trial and who meet eligibility will be recruited from the Mayo Clinic HEN program. Suitable subjects will be identified when they present at the initial HEN visit prior to undergoing enteral tube placement.

Written informed consent will be obtained from all individuals who participate in the study. The principal investigator or member of study team meet with each participant, review the consent form in detail and confirm the subject's understanding of the study. The study team will answer all questions posed by the participants and when convinced that the subject verbally demonstrates understanding of the protocol, they will obtain a signed consent. Only designated staff members are authorized to obtain informed consent.

At the pre-enteral tube visit, subjects will complete a gastrointestinal quality of life (QoL) questionnaire which will form the baseline assessment for symptoms and functional status. Body composition will be measured using Bio-impedance analysis (BIA; InBodyâ„¢). A stool specimen will be obtained for analysis of the gut microbiome at baseline. Baseline clinical data such as current medical problems will be recorded.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective Randomized ControlledProspective Randomized Controlled
Masking:
Triple (Participant, Care Provider, Investigator)
Masking Description:
The randomization list will be generated using http://www.randomization.com and the investigator team will be blinded at enrollment using supplement codes. A designated study coordinator will hold the randomization codes and the codes will be revealed to the investigators only after the statistical analysis is complete.
Primary Purpose:
Supportive Care
Official Title:
The Effect of Blenderized Tube Feeding on Enteral Nutrition Tolerance and the Gut Microbiome: A Pilot Study
Actual Study Start Date :
Jan 11, 2019
Anticipated Primary Completion Date :
Nov 30, 2022
Anticipated Study Completion Date :
Jan 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Polymeric Tube Feeds

This arm will be receiving Polymeric Tube Feeds as a part of the regular HEN Protocol.

Dietary Supplement: Polymeric Tube Feeds
Polymeric tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with blenderized tube feeds

Active Comparator: Blenderized Tube Feeds

This arm will be receiving Blenderized tube feeds as a part of the regular HEN Protocol.

Dietary Supplement: Blenderized Tube Feeds
Blenderized tube feeds will be given to HEN patients to assess the percentage of goal calories provided in comparison with polymeric tube feeds

Outcome Measures

Primary Outcome Measures

  1. Percentage of goal calories provided [4-6 weeks]

Secondary Outcome Measures

  1. Gut microbiome [1 week, 4-6 weeks]

    A stool specimen will be collected to assess the composition of the gut microbiome at baseline and at the follow-up visit.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. All subjects who are above 18 years of age, who present to Mayo Clinic HEN program for initial evaluation prior to enteral tube placement

  2. Require enteral nutrition support for at least 4-6 weeks from enrollment

Exclusion Criteria:
  1. Patients with type 1 or 2 diabetes will be excluded due to the known pre-existing changes in the gut microbiome in this population.

  2. Patients who have had exposure to probiotics, prebiotics or antibiotics in the preceding 4 weeks will be excluded.

  3. Known allergy or intolerance to study products will be excluded.

  4. Patients on parenteral nutrition will be excluded.

  5. If oral feeding accounts for >25% of daily caloric intake.

  6. Presence of entero-cutaneous fistula

  7. Patients with short bowel syndrome will be excluded.

  8. Patients who have had bariatric surgery or other alteration of GI tract will be excluded.

  9. Hematologic malignancy with absolute neutrophil count < 500/mm3

  10. History of renal or liver transplant or on transplant list.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo Clinic in Rochester Rochester Minnesota United States 55905

Sponsors and Collaborators

  • Mayo Clinic

Investigators

  • Principal Investigator: Manpreet S Mundi, MD, Mayo Clinic

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Manpreet S. Mundi, Principal Investigator, Mayo Clinic
ClinicalTrials.gov Identifier:
NCT03795870
Other Study ID Numbers:
  • 18-004416
First Posted:
Jan 8, 2019
Last Update Posted:
Apr 6, 2022
Last Verified:
Apr 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Manpreet S. Mundi, Principal Investigator, Mayo Clinic

Study Results

No Results Posted as of Apr 6, 2022